Online citations, reference lists, and bibliographies.
← Back to Search

The Oncogenic STP Axis Promotes Triple-negative Breast Cancer Via Degradation Of The REST Tumor Suppressor.

Kristen L. Karlin, G. Mondal, Jessica Hartman, S. Tyagi, Sarah J Kurley, C. Bland, T. Y. Hsu, A. Renwick, Justin E. Fang, I. Migliaccio, Celetta Callaway, Amritha Nair, Rocio Dominguez Vidana, D. Nguyen, C. Osborne, R. Schiff, L. Yu-lee, S. Jung, D. Edwards, S. Hilsenbeck, J. Rosen, X. Zhang, C. Shaw, F. Couch, T. Westbrook
Published 2014 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Defining the molecular networks that drive breast cancer has led to therapeutic interventions and improved patient survival. However, the aggressive triple-negative breast cancer subtype (TNBC) remains recalcitrant to targeted therapies because its molecular etiology is poorly defined. In this study, we used a forward genetic screen to discover an oncogenic network driving human TNBC. SCYL1, TEX14, and PLK1 ("STP axis") cooperatively trigger degradation of the REST tumor suppressor protein, a frequent event in human TNBC. The STP axis induces REST degradation by phosphorylating a conserved REST phospho-degron and bridging REST interaction with the ubiquitin-ligase βTRCP. Inhibition of the STP axis leads to increased REST protein levels and impairs TNBC transformation, tumor progression, and metastasis. Expression of the STP axis correlates with low REST protein levels in human TNBCs and poor clinical outcome for TNBC patients. Our findings demonstrate that the STP-REST axis is a molecular driver of human TNBC.
This paper references
10.1038/sj.onc.1206790
Reduced expression of the neuron restrictive silencer factor permits transcription of glycine receptor α1 subunit in small-cell lung cancer cells
C. Gurrola-Díaz (2003)
10.1038/sj.onc.1207389
The many faces of β-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer
S. Fuchs (2004)
10.1126/SCIENCE.2470152
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
D. Slamon (1989)
10.1038/ng1219
Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes
C. Zuccato (2003)
10.1016/S1567-133X(03)00036-X
Sequence and expression of testis-expressed gene 14 (Tex14): a gene encoding a protein kinase preferentially expressed during spermatogenesis.
M. Wu (2003)
10.1038/nprot.2006.201
Design and implementation of bimolecular fluorescence complementation (BiFC) assays for the visualization of protein interactions in living cells
T. Kerppola (2006)
10.1523/JNEUROSCI.23-06-02112.2003
Ischemic Insults Derepress the Gene Silencer REST in Neurons Destined to Die
Agata Calderone (2003)
10.1016/0092-8674(95)90298-8
REST: A mammalian silencer protein that restricts sodium channel gene expression to neurons
J. Chong (1995)
10.1038/sj.onc.1209068
SWI/SNF complex is essential for NRSF-mediated suppression of neuronal genes in human nonsmall cell lung carcinoma cell lines
H. Watanabe (2006)
10.1158/0008-5472.CAN-07-5644
Subtypes of breast cancer show preferential site of relapse.
M. Smid (2008)
10.1038/sj.onc.1206805
Nerve growth factor overexpression and autocrine loop in breast cancer cells
L. Dollé (2003)
10.1038/nrclinonc.2011.177
Treatment of HER2-positive breast cancer: current status and future perspectives
C. Arteaga (2012)
10.1158/2159-8290.CD-11-0107
Functional viability profiles of breast cancer.
R. Brough (2011)
10.1038/sj.embor.7401001
Mutation in the Scyl1 gene encoding amino‐terminal kinase‐like protein causes a recessive form of spinocerebellar neurodegeneration
W. Schmidt (2007)
10.1158/0008-5472.CAN-12-2633
Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.
V. Maire (2013)
10.1038/onc.2010.321
Regulation of the NRSF/REST gene by methylation and CREB affects the cellular phenotype of small-cell lung cancer
A. Kreisler (2010)
10.1371/journal.pgen.1000979
The Transcription Factor REST Is Lost in Aggressive Breast Cancer
Matthew P. Wagoner (2010)
10.1038/nrm1547
Function and regulation of cullin–RING ubiquitin ligases
M. D. Petroski (2005)
10.1038/nature06780
SCFβ-TRCP controls oncogenic transformation and neural differentiation through REST degradation
T. Westbrook (2008)
10.1158/1078-0432.CCR-09-1380
Targeting Polo-like Kinase in Cancer Therapy
Y. Degenhardt (2010)
10.1056/NEJM199811263392207
Tamoxifen in the Treatment of Breast Cancer
O. Ck (1998)
10.1126/science.7871435
The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes
C. Schoenherr (1995)
10.1126/science.1141319
Genome-Wide Mapping of in Vivo Protein-DNA Interactions
D. S. Johnson (2007)
10.1038/nature11412
Comprehensive molecular portraits of human breast tumors
D. Koboldt (2012)
10.1038/nrc2964
Shared and separate functions of polo-like kinases and aurora kinases in cancer
S. Lens (2010)
10.1016/j.devcel.2008.05.009
Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis.
Jiaqi Yang (2008)
10.1038/nature10983
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
C. Curtis (2012)
10.1038/nrclinonc.2012.159
What are we learning from the cancer genome?
E. Collisson (2012)
10.1038/nrm2653
Polo-like kinases: conservation and divergence in their functions and regulation
V. Archambault (2009)
10.1073/PNAS.0402442101
Role of Polo-like kinase in the degradation of early mitotic inhibitor 1, a regulator of the anaphase promoting complex/cyclosome.
Yakir Moshe (2004)
10.1016/j.cytogfr.2012.06.004
Neurotrophins and their receptors in breast cancer.
H. Hondermarck (2012)
A splice variant of the neuron-restrictive silencer factor repressor is expressed in small cell lung cancer: a potential role in derepression of neuroendocrine genes and a useful clinical marker.
J. Coulson (2000)
10.1634/theoncologist.2009-0010
Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.
P. Schöffski (2009)
10.1128/MCB.01392-09
TEX14 Interacts with CEP55 To Block Cell Abscission
T. Iwamori (2010)
10.1126/SCIENCE.1075762
The Protein Kinase Complement of the Human Genome
G. Manning (2002)
10.1016/j.conb.2005.08.015
The many faces of REST oversee epigenetic programming of neuronal genes
N. Ballas (2005)
10.1023/B:BREA.0000010704.17479.8a
Altered Expression and Activation of the Nerve Growth Factor Receptors TrkA and p75 Provide the First Evidence of Tumor Progression to Effusion in Breast Carcinoma
B. Davidson (2004)
10.1016/j.cell.2005.03.013
REST and Its Corepressors Mediate Plasticity of Neuronal Gene Chromatin throughout Neurogenesis
N. Ballas (2005)
10.1016/j.cub.2006.12.037
BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo
M. Steegmaier (2007)
10.1523/JNEUROSCI.4045-13.2014
Casein Kinase 1 Suppresses Activation of REST in Insulted Hippocampal Neurons and Halts Ischemia-Induced Neuronal Death
Naoki Kaneko (2014)
10.1073/PNAS.0307700101
M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFbeta-TrCP.
N. Watanabe (2004)
10.2217/fon.09.68
What's positive about 'triple-negative' breast cancer?
S. Hurvitz (2009)
10.1016/j.molcel.2012.01.013
Tex14, a Plk1-regulated protein, is required for kinetochore-microtubule attachment and regulation of the spindle assembly checkpoint.
G. Mondal (2012)
10.1038/onc.2009.61
TrkA overexpression enhances growth and metastasis of breast cancer cells
C. Lagadec (2009)
10.1016/j.devcel.2008.04.014
Polo on the Rise-from Mitotic Entry to Cytokinesis with Plk1.
Mark Petronczki (2008)
10.1101/GAD.13.3.270
The SCFβ-TRCP–ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IκBα and β-catenin and stimulates IκBα ubiquitination in vitro
J. T. Winston (1999)
10.1038/nrclinonc.2009.234
Management of breast cancer with targeted agents: importance of heterogenicity
S. Cosimo (2010)
10.1038/nature03799
Genes that mediate breast cancer metastasis to lung
A. Minn (2005)
10.1038/nature13163
REST and Stress Resistance in Aging and Alzheimer’s Disease
T. Lu (2014)
10.1016/j.molonc.2010.11.003
Deconstructing the molecular portraits of breast cancer
A. Prat (2011)
10.1016/j.cell.2005.03.033
A Genetic Screen for Candidate Tumor Suppressors Identifies REST
T. Westbrook (2005)
10.1038/nature06641
Control of chromosome stability by the β-TrCP–REST–Mad2 axis
D. Guardavaccaro (2008)



This paper is referenced by
10.1101/309302
CRISPRCloud2: A cloud-based platform for deconvolving CRISPR screen data
Hyun-hwan Jeong (2018)
10.1371/journal.pone.0178680
SCYL1 does not regulate REST expression and turnover
S. Gingras (2017)
10.1158/1078-0432.CCR-18-2423
High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients
J. Chen (2019)
10.1038/ng0329-473d
Corrigendum: Mutations in the transcriptional repressor REST predispose to Wilms tumor
S. Mahamdallie (2016)
pseudokinases in neuronal function and survival
S. Pelletier (2016)
10.1101/gad.305631.117
Hyperactive mTOR and MNK1 phosphorylation of eIF4E confer tamoxifen resistance and estrogen independence through selective mRNA translation reprogramming.
Phillip Geter (2017)
10.1038/ng.3440
Mutations in the transcriptional repressor REST predispose to Wilms tumor
S. Mahamdallie (2015)
10.1371/journal.pone.0206008
Chromosome 19 miRNA cluster and CEBPB expression specifically mark and potentially drive triple negative breast cancers
G. Jinesh (2018)
10.3390/cancers9100131
The Emerging Role of Polo-Like Kinase 1 in Epithelial-Mesenchymal Transition and Tumor Metastasis
Z. Fu (2017)
10.3390/genes10030208
The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor?
G. de Cárcer (2019)
10.1016/j.canlet.2017.02.031
Roles of cancer/testis antigens (CTAs) in breast cancer.
Yongfei Li (2017)
10.12659/MSM.910916
Identification of Key Genes and Pathways Associated with RUNX1 Mutations in Acute Myeloid Leukemia Using Bioinformatics Analysis.
Fangxiao Zhu (2018)
10.3892/ol.2017.5860
FBP1 expression is associated with basal-like breast carcinoma
L. Shi (2017)
10.3390/GENES10030208
The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor?
G. Cárcer (2019)
10.1523/JNEUROSCI.2282-17.2018
Overlapping Role of SCYL1 and SCYL3 in Maintaining Motor Neuron Viability
E. Kuliyev (2018)
10.1016/j.tranon.2016.10.003
PLK1, A Potential Target for Cancer Therapy
Zhixian Liu (2017)
Semantic Scholar Logo Some data provided by SemanticScholar